To validate the leukemogenic role of miR-126 observed in the murine inv(16) AML model, we knocked down miR-126 in human inv(16) AML CD34+ and CD34− cells using shmiR-126 and assessed cell differentiation, proliferation, and apoptosis rates (Supplementary Fig. 7a). Here, CD34 is linked to acute myeloid leukemia.